Risk acceptance in multiple sclerosis paciente on natalizumabe treatment

• Grant number: 15/22721-7
• Support type: Scholarships in Brazil - Scientific Initiation
• Effective date (Start): February 01, 2016
• Effective date (End): January 31, 2017
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Principal researcher: Denis Bernardi Bichuetti
• Grantee: Carolina Azze Franco
• Home Institution: Escola Paulista de Medicina (EPM). Universidade Federal de São Paulo (UNIFESP). Campus São Paulo. São Paulo , SP, Brazil

Abstract

In the last decade, new drugs for multiple sclerosis have been tested and approved. Among them is natalizumab, that despite its high efficacy has its use limited by the risk of developing progressive multifocal leukoencephalopathy. By applying, a questionnaire with inclusion of patients diagnosed with relapsing-remitting multiple sclerosis, we aimed to assess how patients assess the risks of treatment with natalizumab and the factors involved in this evaluation.